在阿尔茨海默氏病中溶解体功能障碍的调节机制和治疗影响
Yeji Kim1, Tae-Young Ha2,3, Myung-Shik Lee4,5
1Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences & Technology, Gachon University, Incheon 21999, Korea.
International journal of biological sciences
|February 3, 2025
概括
溶解体功能障碍通过破坏细胞废物清除,导致阿尔茨海默病 (AD). 向 lysosomal 途径为AD 治疗提供了有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 在病理上是由粉样β (Aβ) 斑块,神经纤维状结 (NFT) 和神经元损失定义的.
- 自-溶解体通路对于细胞平衡至关重要,降解受损的组件和蛋白质聚合物,如Aβ.
- 溶解体是这种途径的核心,分解细胞碎片和错误折叠的蛋白质,这些蛋白质与神经退行性疾病有关.
研究的目的:
- 审查 lysosomal 功能障碍在阿尔茨海默病 (AD) 病理生理学中的关键作用.
- 探索微质溶酶体功能障碍和溶酶体应激反应 (LSR) 在AD中的参与.
- 讨论治疗策略,旨在纠正AD治疗的溶酶体功能障碍.
主要方法:
- 文献综述侧重于遗传因素,酸性缺陷和其他导致AD的溶酶体功能障碍的因素.
- 检查微质细胞中 lysosomal 功能障碍的作用及其对AD病理学的影响.
- 分析与AD相关的神经元损伤中的溶酶体应激反应 (LSR) 机制.
主要成果:
- Lysosomal 功能障碍,包括酸性化和遗传因素的问题,对AD 病原发生有显著的贡献.
- 微质 lysosomal 功能障碍加剧了阿尔茨海默病理,突出了免疫细胞的作用.
- 溶解体应激反应 (LSR) 是AD中神经元损伤的一个关键细胞反应.
结论:
- lysosomal 功能障碍是阿尔茨海默病的中心机制,影响神经元和微质功能.
- 针对 lysosomal 蛋白解的治疗策略,如激活 lysosomal 活性和调节 TFEB,显示了AD 治疗的潜力.
- 对溶酶体功能障碍新兴方法的进一步研究有望为新的AD疗法提供希望.
相关概念视频
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Parkinson's Disease: Overview
447
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
447


